CD4 and cancer: T-bsAbs are known to recruit T cells to the tumor and cause MHC-unrestricted killing of cancer cells by both CD8 + and CD4 + T cells, which enables neoantigen release and thus a potential expansion of neoantigen-specific T cells [5, 39–42].